January 14th, 2011
FDA Warns About Severe Liver Injury Associated with Multaq (Dronedarone)
Larry Husten, PHD
The FDA has released a safety communication about severe liver injury associated with Multaq (dronedarone). The FDA said that information about the risk of liver injury would be added to the dronedarone label. The drug’s manufacturer, Sanofi-Aventis, has also sent a letter to healthcare professionals informing them of the warning. The FDA is recommending that doctors advise […]
NEJM Journal Watch — Recent Cardiology Articles- Do SGLT-2 Inhibitors Reduce Cancer-Related Cardiotoxicity?
- Perioperative Cardiovascular Management for Patients Undergoing Noncardiac Surgery
- Is Intracranial Atherosclerotic Disease Associated with Dementia Risk?
- What Is the Optimal Hemoglobin Transfusion Threshold in Patients with Myocardial Infarction?
- Renal Denervation for Managing Hypertension